未定义/非恶性肝结节与DAA治疗丙肝肝硬化患者早期HCC发生相关
这项前瞻性多中心研究纳入1161例无HCC肝硬化和124例曾接受根治性HCC治疗的丙肝肝硬化患者,均接受DAA治疗。中位随访17个月和16个月,无HCC组年HCC发生率为3.1/100人年,有HCC史组年复发率为29.9/100人年。未定义/非恶性肝结节(UNMNs)与无HCC组早期HCC发生独立相关(HR 3.11,95%CI 1.47-6.57,p=0.003),但未观察到肿瘤侵袭性增加。
要点
- DAA治疗丙肝肝硬化患者中,UNMNs是无HCC组早期HCC发生的独立危险因素。
- 有HCC根治史患者DAA治疗后HCC复发率高,年复发率29.9/100人年。
- DAA治疗后早期HCC发生率高,但未伴随肿瘤临床侵袭性增加。
核心结论
- DAA治疗的丙肝肝硬化患者中,UNMNs患者早期新发HCC发生率高,有HCC治疗史者复发率高,但肿瘤侵袭性未增加。
研究设计与样本
- 前瞻性多中心研究,连续纳入1161例无HCC肝硬化患者(组1)和124例曾接受根治性HCC治疗的肝硬化患者(组2),均接受DAA治疗。
主要发现
- 组1中位随访17个月,新发HCC 48例,年发生率3.1/100人年,75%为BCLC 0-A期。
- 组2中位随访16个月,HCC复发40例,年平均复发率29.9/100人年,83%为BCLC 0-A期。
- 组1中UNMNs患者HCC即时发生率峰值在4.2个月,组2在7.7个月。
- 多变量Cox回归显示,UNMNs(HR 3.11;95%CI 1.47-6.57;p=0.003)、入组前任何时间出现腹水(HR 3.04;95%CI 1.23-7.51;p=0.02)和AFP对数(HR 1.90;95%CI 1.05-3.44;p=0.03)与新发HCC独立相关。
- HCC复发相关因素为酒精滥用史(HR 2.10;95%CI 1.08-4.09;p=0.03)和HCC复发史(HR 2.87;95%CI 1.35-6.09;p=0.006)。
临床怎么用
- 对DAA治疗的丙肝肝硬化患者,尤其存在UNMNs者,应在治疗后早期密切监测HCC发生。
- 有HCC根治史的患者DAA治疗后需加强HCC复发监测。
局限性
- UNMNs是否为临床不可检测的癌细胞巢或癌前病变并在DAA治疗后进展为显性HCC,尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIM: An unexpected early increase in incidence, recurrence and clinical aggressiveness of hepatocellular carcinoma (HCC) has been reported (and refuted) in patients with HCV-related cirrhosis following direct-acting antiviral (DAA) treatment. To address this controversy, we performed a prospective multicenter study on consecutively enrolled cirrhotic patients, with or without a history of HCC, undergoing DAA therapy. PATIENTS AND METHODS: A total of 1,161 HCC-free cirrhotics (group 1) and 124 cirrhotics who had received a curative treatment for an HCC (group 2) were enrolled. Clinical features, including presence of undefined/non-malignant liver nodules (UNMNs), were analyzed with respect to HCC incidence and recurrence. RESULTS: During a median study time of 17 months in group 1 and 16 months in group 2, de novo HCC developed in 48 patients (yearly incidence 3.1/100 patient-years, 75% BCLC 0-A) and recurred in 40 (mean yearly incidence 29.9/100 patient-years, 83% BCLC 0-A). A peak of HCC instant incidence was observed at 4.2 months in group 1 patients with UNMNs, and at 7.7 months in group 2. By multivariable Cox regression models, UNMNs (hazard ratio [HR] 3.11; 95% CI 1.47-6.57: p = 0.003), ascites detected any time before enrolment (HR 3.04; 95% CI 1.23-7.51; p = 0.02), and alpha-fetoprotein log-value (HR 1.90; 95% CI 1.05-3.44; p = 0.03) were the variables independently associated with the incidence of de novo HCC, while history of alcohol abuse (HR 2.10; 95% CI 1.08-4.09; p = 0.03) and history of recurrence of HCC (HR 2.87; 95% CI 1.35-6.09; p = 0.006) were associated with HCC recurrence. CONCLUSION: An early high incidence of both de novo HCC, in patients with UNMNs, and recurrent HCC was observed in DAA-treated patients; this was not accompanied by increased tumor aggressiveness. LAY SUMMARY: This prospective study focuses on the risk of developing de novo or recurrent hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) treatment in patients with hepatitis C-related cirrhosis. We found that DAA treatment was associated with an early high HCC incidence in patients with undefined or non-malignant nodules, as well as in those with a history of complete response to HCC treatment. Whether this is related to the presence of clinically undetectable nests of cancer cells or to precancerous lesions that may progress to overt HCC upon DAA treatment remains unanswered. No evidence of increased clinical aggressiveness was reported in de novo or recurrent HCC.
引用
- Sangiovanni A, Alimenti E, Gattai R, et al. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol. 2020. PMID: 32243959. doi:10.1016/j.jhep.2020.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。